Terms: = Liver cancer AND PCSK7, Q16549, 9159, ENSG00000160613, PC8, SPC7, PC7, LPC AND Treatment
18 results:
1. Alterations in serum metabolic profiles of early-stage hepatocellular carcinoma patients after radiofrequency ablation therapy.
Zhang F; Wu J; Zhang L; Zhang J; Yang R
J Pharm Biomed Anal; 2024 Jun; 243():116073. PubMed ID: 38484637
[TBL] [Abstract] [Full Text] [Related]
2. Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis.
Wu WR; Shi XD; Zhang FP; Zhu K; Zhang R; Yu XH; Qin YF; He SP; Fu HW; Zhang L; Zeng H; Zhu MS; Xu LB; Wong PP; Liu C
Oncogene; 2022 Apr; 41(16):2340-2356. PubMed ID: 35256782
[TBL] [Abstract] [Full Text] [Related]
3. Significant metabolic alterations in patients with hepatitis B virus replication observed via serum untargeted metabolomics shed new light on hepatitis B virus infection.
Yu L; Zeng Z; Tan H; Feng Q; Zhou Q; Hu J; Li Y; Wang J; Yang W; Feng J; Xu B
J Drug Target; 2022 Apr; 30(4):442-449. PubMed ID: 34844491
[TBL] [Abstract] [Full Text] [Related]
4. The Impact of Geography in Hepatocellular Carcinoma: A Retrospective Population Based Study.
Yu IS; Liu SL; Zaborska V; Raycraft T; Gill S; Lim H; Davies JM
Curr Oncol; 2021 Jan; 28(1):396-404. PubMed ID: 33445517
[TBL] [Abstract] [Full Text] [Related]
5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract] [Full Text] [Related]
6. RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.
Krishna-Subramanian S; Singer S; Armaka M; Banales JM; Holzer K; Schirmacher P; Walczak H; Kollias G; Pasparakis M; Kondylis V
Cell Death Differ; 2019 Dec; 26(12):2710-2726. PubMed ID: 30988397
[TBL] [Abstract] [Full Text] [Related]
7. Modulation of Lipid Metabolism by Celastrol.
Zhang T; Zhao Q; Xiao X; Yang R; Hu D; Zhu X; Gonzalez FJ; Li F
J Proteome Res; 2019 Mar; 18(3):1133-1144. PubMed ID: 30706713
[TBL] [Abstract] [Full Text] [Related]
8. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
Li XF; Chen C; Xiang DM; Qu L; Sun W; Lu XY; Zhou TF; Chen SZ; Ning BF; Cheng Z; Xia MY; Shen WF; Yang W; Wen W; Lee TKW; Cong WM; Wang HY; Ding J
Hepatology; 2017 Dec; 66(6):1934-1951. PubMed ID: 28714104
[TBL] [Abstract] [Full Text] [Related]
9. The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury.
Lukacs-Kornek V; Lammert F
J Hepatol; 2017 Mar; 66(3):619-630. PubMed ID: 27826058
[TBL] [Abstract] [Full Text] [Related]
10. Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma.
Krautbauer S; Meier EM; Rein-Fischboeck L; Pohl R; Weiss TS; Sigruener A; Aslanidis C; Liebisch G; Buechler C
Biochim Biophys Acta; 2016 Nov; 1861(11):1767-1774. PubMed ID: 27570113
[TBL] [Abstract] [Full Text] [Related]
11. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.
Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879
[TBL] [Abstract] [Full Text] [Related]
12. Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR-γ) in advanced prostate cancer.
Rogenhofer S; Ellinger J; Kahl P; Stoehr C; Hartmann A; Engehausen D; Wieland WF; Müller SC; Hofstädter F; Walter B
Anticancer Res; 2012 Aug; 32(8):3479-83. PubMed ID: 22843934
[TBL] [Abstract] [Full Text] [Related]
13. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract] [Full Text] [Related]
14. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract] [Full Text] [Related]
15. liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Kurosaki I; Kawachi Y; Nihei K; Tsuchiya Y; Aono T; Yokoyama N; Shimizu T; Hatakeyama K
Pancreas; 2009 Mar; 38(2):161-7. PubMed ID: 18797423
[TBL] [Abstract] [Full Text] [Related]
16. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract] [Full Text] [Related]
17. Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes.
Gwak GY; Yoon JH; Lee SH; Lee SM; Lee HS; Gores GJ
J Cancer Res Clin Oncol; 2006 Dec; 132(12):771-9. PubMed ID: 16810500
[TBL] [Abstract] [Full Text] [Related]
18. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer.
Nakayama S; Takeda S; Kawase Y; Inoue S; Kaneko T; Nakao A
Ann Surg; 2004 Nov; 240(5):840-4. PubMed ID: 15492566
[TBL] [Abstract] [Full Text] [Related]
